Cytokinetics CYTK Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $105.82M+20.2% | $88.04M+0.9% | $87.21M+1.7% | $85.74M+346% | $19.22M+4.0% | ||
| $411.71M-0.7% | $414.45M+2.7% | $403.68M+3.8% | $389.06M+9.3% | $356.1M+4.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | $284.27M+11.5% | $254.89M+5.3% | $242.08M+6.6% | $227.18M+5.5% | ||
| $11.2M+10.6% | $10.13M+5.0% | $9.65M+2.9% | $9.38M-1.3% | $9.5M-0.3% | ||
| $746.06M+6.5% | $700.3M+6.1% | $660.14M+4.3% | $632.72M+8.2% | $584.86M+5.4% | ||
| $746.06M+6.5% | $700.3M+6.1% | $660.14M+4.3% | $632.72M+8.2% | $584.86M+5.4% | ||
| -$640.25M-4.6% | -$612.26M-6.9% | -$572.93M-4.7% | -$546.98M+3.3% | -$565.64M-5.5% | ||
| -605.1%+90.4pp | -695.4%-38.5pp | -656.9%-19.0pp | -638%+2,305pp | -2,943.3%-40.6pp | ||
| $51.23M+12.4% | $45.58M+13.3% | $40.24M+6.4% | $37.82M-4.2% | $39.47M+4.7% | ||
| $45.74M-5.5% | $48.42M-6.8% | $51.96M-11.6% | $58.77M+2.5% | $57.32M+11.2% | ||
| -$829.61M-5.7% | -$784.96M-4.4% | -$751.94M-24.0% | -$606.31M+1.5% | -$615.26M-4.4% | ||
| -784%+108pp | -891.6%-29.4pp | -862.2%-155pp | -707.2%+2,494pp | -3,201.5%-10.4pp | ||
| -$6.84-4.7% | -$6.53-3.8% | -$6.29-23.3% | -$5.10+3.6% | -$5.29-0.6% | ||
| -$6.84-4.7% | -$6.53-3.8% | -$6.29-23.3% | -$5.10+3.6% | -$5.29-0.6% | ||
| 482.8M+1.0% | 478M+1.7% | 469.9M+0.5% | 467.6M+2.2% | 457.4M+3.8% | ||
| 482.8M+1.0% | 478M+1.7% | 469.9M+0.5% | 467.6M+2.2% | 457.4M+3.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$832.77M-5.9% | -$786.72M-3.9% | -$757.3M-25.1% | -$605.45M+1.3% | -$613.18M-4.4% | ||
| $6.1M+45.2% | $4.2M-6.7% | $4.5M0.0% | $4.5M+400% | $900K-30.8% | ||
| —— | —— | —— | —— | —— | ||
| $4.82M+332% | $1.11M-28.8% | $1.56M-81.4% | $8.41M+614% | $1.18M-92.3% | ||
| $41.76M+24.3% | $33.6M+94.1% | $17.31M+13.8% | $15.21M+182% | $5.39M-62.0% | ||
| $500K-83.0% | $2.93M-59.2% | $7.18M-20.1% | $8.98M+335% | -$3.82M-257% | ||
| —— | —— | -$18.1M+40.7% | -$30.5M-94.3% | -$15.7M+19.9% | ||
| $527.47M+0.6% | $524.46M+26.0% | $416.14M+367% | $89.1M-89.3% | $831.57M-10.6% | ||
| -$523.85M-2.7% | -$510.01M-17.8% | -$432.93M-1.4% | -$426.92M-7.3% | -$398M-0.5% | ||
| $63.03M+8.1% | $58.29M+4.3% | $55.88M+2.9% | $54.29M+3.1% | $52.67M+7.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$801K+15.9% | -$952K-1,033% | -$84K-133% | ||
| $1.01B-4.9% | $1.06B+26.8% | $838.65M+16.9% | $717.6M-45.2% | $1.31B+1.3% | ||
| $25.07M+1.1% | $24.81M+21.3% | $20.45M+73.3% | $11.8M+23.3% | $9.57M+145% | ||
| $105.82M+20.2% | $88.04M+0.9% | $87.21M+1.7% | $85.74M+346% | $19.22M+4.0% | ||
| $119.13M+6.1% | $112.29M+3.9% | $108.03M+5.2% | $102.69M+2.9% | $99.78M+2.0% | ||
| -$640.25M-4.6% | -$612.26M-6.9% | -$572.93M-4.7% | -$546.98M+3.3% | -$565.64M-5.5% | ||
| -$629.04M-4.5% | -$602.13M-6.9% | -$563.29M-4.8% | -$537.6M+3.3% | -$556.14M-5.6% | ||
| -$629.04M-4.5% | -$602.13M-6.9% | -$563.29M-4.8% | -$537.6M+3.3% | -$556.14M-5.6% | ||
| -594.5%+89.5pp | -683.9%-38.1pp | -645.9%-18.9pp | -627%+2,267pp | -2,893.9%-42.7pp | ||
| -$640.25M-4.6% | -$612.26M-6.9% | -$572.93M-4.7% | -$546.98M+3.3% | -$565.64M-5.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Cytokinetics's revenue?
- Cytokinetics (CYTK) generated $105.8M in revenue over the trailing twelve months, up 450.6% year over year.
- Is Cytokinetics profitable?
- Cytokinetics is not currently profitable: it reported a net loss of $829.6M over the trailing twelve months, a -784.0% net margin.
- What is Cytokinetics's earnings per share?
- Cytokinetics's diluted EPS over the trailing twelve months is $-6.84.
- Where does Cytokinetics's income statement data come from?
- Every line is extracted from Cytokinetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
